Literature DB >> 29133344

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial.

Silvio E Inzucchi1, Hristo Iliev2, Egon Pfarr2, Bernard Zinman3.   

Abstract

Year:  2017        PMID： 29133344     DOI： 10.2337/dc17-1551

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  46 in total

1.  Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.

Authors:  Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

2.  Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use.

Authors:  Louis Potier; Ronan Roussel; Gilberto Velho; Pierre-Jean Saulnier; Anisoara Bumbu; Odette Matar; Fabrice Schneider; Stéphanie Ragot; Michel Marre; Kamel Mohammedi; Samy Hadjadj
Journal:  Diabetologia       Date:  2019-02-26       Impact factor: 10.122

Review 3.  The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.

Authors:  Robert J Chilton; Kelly M Gallegos; José Silva-Cardoso; Rene Oliveros; Son Pham
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

4.  Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation.

Authors:  Matilde Monteiro-Soares; Inês Ribeiro-Vaz; Edward J Boyko
Journal:  Diabetologia       Date:  2019-04-02       Impact factor: 10.122

Review 5.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 6.  Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.

Authors:  Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

Review 7.  Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.

Authors:  Beatrice C Lupsa; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 8.  Empagliflozin: A Review in Type 2 Diabetes.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 9.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

Review 10.  Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.

Authors:  Laleh Razavi-Nematollahi; Faramarz Ismail-Beigi
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.